161 related articles for article (PubMed ID: 11908825)
21. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7.
Padhye VV; Zhao T; Doyle MP
J Med Microbiol; 1989 Nov; 30(3):219-26. PubMed ID: 2479749
[TBL] [Abstract][Full Text] [Related]
22. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker.
Heath-Engel HM; Lingwood CA
Angiogenesis; 2003; 6(2):129-41. PubMed ID: 14739619
[TBL] [Abstract][Full Text] [Related]
23. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias.
Arab S; Russel E; Chapman WB; Rosen B; Lingwood CA
Oncol Res; 1997; 9(10):553-63. PubMed ID: 9507533
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice.
Kuribayashi T; Seita T; Fukuyama M; Furuhata K; Honda M; Matsumoto M; Seguchi H; Yamamoto S
J Infect Chemother; 2006 Oct; 12(5):251-6. PubMed ID: 17109087
[TBL] [Abstract][Full Text] [Related]
25. Glycolipid receptors for verotoxin and Helicobacter pylori: role in pathology.
Lingwood CA
Biochim Biophys Acta; 1999 Oct; 1455(2-3):375-86. PubMed ID: 10571026
[TBL] [Abstract][Full Text] [Related]
26. Apparent cooperativity in multivalent verotoxin-globotriaosyl ceramide binding: kinetic and saturation binding studies with [(125)I]verotoxin.
Peter MG; Lingwood CA
Biochim Biophys Acta; 2000 Jun; 1501(2-3):116-24. PubMed ID: 10838185
[TBL] [Abstract][Full Text] [Related]
27. Brefeldin A and filipin distinguish two globotriaosyl ceramide/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity.
Khine AA; Tam P; Nutikka A; Lingwood CA
Glycobiology; 2004 Aug; 14(8):701-12. PubMed ID: 15102715
[TBL] [Abstract][Full Text] [Related]
28. Selenium reduces enterohemorrhagic Escherichia coli O157:H7 verotoxin production and globotriaosylceramide receptor expression on host cells.
Surendran-Nair M; Kollanoor-Johny A; Ananda-Baskaran S; Norris C; Lee JY; Venkitanarayanan K
Future Microbiol; 2016 Jun; 11():745-56. PubMed ID: 27191971
[TBL] [Abstract][Full Text] [Related]
29. Self-assembled monolayers of globotriaosylceramide (Gb3) mimics: surface-specific affinity with shiga toxins.
Miura Y; Sasao Y; Dohi H; Nishida Y; Kobayashi K
Anal Biochem; 2002 Nov; 310(1):27-35. PubMed ID: 12413469
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Vero cell cytotoxic activity in Escherichia coli O157:H7 lysates by globotriaosylceramide, Gb3, from bovine milk.
Watarai S; Tana ; Inoue K; Kushi Y; Isogai E; Yokota K; Naka K; Oguma K; Kodama H
Biosci Biotechnol Biochem; 2001 Feb; 65(2):414-9. PubMed ID: 11302178
[TBL] [Abstract][Full Text] [Related]
31. Adamantyl globotriaosyl ceramide: a monovalent soluble mimic which inhibits verotoxin binding to its glycolipid receptor.
Mylvaganam M; Lingwood CA
Biochem Biophys Res Commun; 1999 Apr; 257(2):391-4. PubMed ID: 10198223
[TBL] [Abstract][Full Text] [Related]
32. Polyisobutylmethacrylate modifies glycolipid binding specificity of verotoxin 1 in thin-layer chromatogram overlay procedures.
Yiu SC; Lingwood CA
Anal Biochem; 1992 Apr; 202(1):188-92. PubMed ID: 1621981
[TBL] [Abstract][Full Text] [Related]
33. Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.
Lingwood CA; Yiu SK
Biochem J; 1992 Apr; 283 ( Pt 1)(Pt 1):25-6. PubMed ID: 1314564
[TBL] [Abstract][Full Text] [Related]
34. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
[TBL] [Abstract][Full Text] [Related]
35. Developmentally regulated Gb3 galactosyltransferase and alpha-galactosidase determine Shiga toxin receptors in intestine.
Mobassaleh M; Koul O; Mishra K; McCluer RH; Keusch GT
Am J Physiol; 1994 Oct; 267(4 Pt 1):G618-24. PubMed ID: 7943326
[TBL] [Abstract][Full Text] [Related]
36. Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.
Bitzan M; Klemt M; Steffens R; Müller-Wiefel DE
Infection; 1993; 21(3):140-5. PubMed ID: 8365810
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of intestinal anti-Gb3 IgA antibody on verotoxin-induced cytotoxicity.
Watarai S; Tana ; Inoue K; Oguma K; Naka K; Kodama H
Lett Appl Microbiol; 2000 Dec; 31(6):449-53. PubMed ID: 11123554
[TBL] [Abstract][Full Text] [Related]
38. Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.
Flagler MJ; Mahajan SS; Kulkarni AA; Iyer SS; Weiss AA
Biochemistry; 2010 Mar; 49(8):1649-57. PubMed ID: 20092352
[TBL] [Abstract][Full Text] [Related]
39. Shiga toxin binding to glycolipids and glycans.
Gallegos KM; Conrady DG; Karve SS; Gunasekera TS; Herr AB; Weiss AA
PLoS One; 2012; 7(2):e30368. PubMed ID: 22348006
[TBL] [Abstract][Full Text] [Related]
40. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.
Mattocks M; Bagovich M; De Rosa M; Bond S; Binnington B; Rasaiah VI; Medin J; Lingwood C
FEBS J; 2006 May; 273(9):2064-75. PubMed ID: 16724420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
